ORGANOVO HOLDINGS INC (ONVO)
US68620A2033 - Common Stock
Unusual volume stocks in Tuesday's session
Unusual volume stocks in Tuesday's session
Which stocks are experiencing notable movement on Monday?
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Curious about the most active stocks on Monday? Find out which stocks are dominating the market action!
Activity analysis on 2024-04-15: most active stocks in today's session.
Gapping stocks in Monday's session
Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
These stocks are moving in today's pre-market session
Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat...
Organovo files for $150M mixed shelf (NASDAQ:ONVO)
Organovo (NASDAQ:ONVO) disclosed in an SEC filing on Friday a prospectus to offer and sell common stock, preferred stock, debt securities, warrants, units...
Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress
SAN DIEGO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a clinical stage biotechnology company focused on developing FXR314...
Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress
Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress
SAN DIEGO, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing...
Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results
Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results
SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing...
CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan
CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan
SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline on November 8, 2023 by Organovo, Inc. (NASDAQ: ONVO), a link was...
Organovo Highlights FXR314 Combination Therapy Potential and Plan
Organovo Highlights FXR314 Combination Therapy Potential and Plan
SAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing...
Organovo to Participate in the H.C. Wainwright Global Investment Conference
Organovo to Participate in the H.C. Wainwright Global Investment Conference
SAN DIEGO, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (Organovo), a clinical stage biotechnology company that is focused...
Organovo up 4% as it boosts timeline for ulcerative colitis asset (NASDAQ:ONVO)
Organovo (ONVO) is up 4% in Wednesday morning trading after the company said that it would accelerate development of FRX314 for ulcerative colitis. Read more here.
Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data
Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data
SAN DIEGO, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (Organovo), a clinical stage biotechnology company that is focused on...